KRIYA 586
Alternative Names: KRIYA-586Latest Information Update: 18 Sep 2024
At a glance
- Originator Kriya Therapeutics
- Class Eye disorder therapies; Gene therapies; Monoclonal antibodies
- Mechanism of Action IGF type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Graves ophthalmopathy
Most Recent Events
- 12 Sep 2024 Pharmacodynamics data from a preclinical trial in Graves ophthalmopathy released by Kriya Therapeutics
- 08 Jan 2024 Kriya therapeutics plans a clinical trial for Graves ophthalmopathy in the end of 2025 (Parenteral)
- 05 Jan 2024 Preclinical trials in Graves ophthalmopathy in USA (Parenteral)